Adipose tissue macrophage markers(M2,etc) altered/target in coronary heart disease-EU | NAVB Message Board Posts

Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  40536 of 40757  at  11/26/2023 6:26:40 PM  by


The following message was updated on 11/26/2023 6:31:06 PM.

Adipose tissue macrophage markers(M2,etc) altered/target in coronary heart disease-EU

 Even though analyzing genes, this study out of the EU confirms Navidea trial perspective that CD206, etc are primary targets in the adipose tissue in coronary heart disease (CAD)

Macrophage polarization markers in subcutaneous, pericardial, and epicardial adipose tissue are altered in patients with coronary heart disease

Bianca Papotti1,2* Trine Baur Opstad1,3 Sissel Åkra1 Theis Tønnessen3,4 Bjørn Braathen4 Charlotte Holst Hansen1 Harald Arnesen1,3 Svein Solheim1 Ingebjørg Seljeflot1,3 Nicoletta Ronda2
  • 1Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway
  • 2Department of Food and Drug, University of Parma, Parma, Italy
  • 3Faculty of Medicine, University of Oslo, Oslo, Norway
  • 4Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway

Background: Epicardial and pericardial adipose tissue (EAT and PAT) surround and protect the heart, with EAT directly sharing the microcirculation with the myocardium, possibly presenting a distinct macrophage phenotype that might affect the inflammatory environment in coronary heart disease (CHD). This study aims to investigate the expression of genes in different AT compartments driving the polarization of AT macrophages toward an anti-inflammatory (L-Galectin 9; CD206) or pro-inflammatory (NOS2) phenotype.

Methods: EAT, PAT, and subcutaneous (SAT) biopsies were collected from 52 CHD patients undergoing coronary artery bypass grafting, and from 22 CTRLs undergoing aortic valve replacement. L-Galectin9 (L-Gal9), CD206, and NOS2 AT gene expression and circulating levels were analyzed through RT-PCR and ELISA, respectively.

Results: L-Gal9, CD206, and NOS2 gene expression was similar in all AT compartments in CHD and CTRLs, as were also L-Gal9 and CD206 circulating levels, while NOS2 serum levels were higher in CHD (p = 0.012 vs. CTRLs). In CTRLs, NOS2 expression was lower in EAT vs. SAT (p = 0.007), while in CHD patients CD206 expression was lower in both SAT and EAT as compared to PAT (p = 0.003, p = 0.006, respectively), suggestive of a possible macrophage reprogramming toward a pro-inflammatory phenotype in EAT. In CHD patients, NOS2 expression in SAT correlated to that in PAT and EAT (p = 0.007, both), CD206 expression correlated positively to L-Gal9 (p < 0.001) only in EAT, and CD206 expression associated with that of macrophage identifying markers in all AT compartments (p < 0.001, all). In CHD patients, subjects with LDL-C above 1.8 mmol/L showed significantly higher NOS2 expression in PAT and EAT as compared to subjects with LDL-C levels below (p < 0.05), possibly reflecting increased cardiac AT pro-inflammatory activation. In SAT and PAT, CD206 expression associated with BMI in both CHD and CTRLs (p < 0.05, all), and with L-Gal9 in EAT, however only in CTRLs (p = 0.002).

Conclusion: CHD seems to be accompanied by an altered cardiac, and especially epicardial AT macrophage polarization. This may represent an important pathophysiological mechanism and a promising field of therapy targeting the excessive AT inflammation, in need of further investigation...

When comparing gene expression levels of the investigated molecules in the different AT compartments, we did not find differences in L-Gal 9 expression between SAT, PAT and EAT in either CTRLs or CHD patients. Several in vitro studies have demonstrated that L-Gal 9 is involved in the modulation of a variety of biological processes, including cell aggregation and adhesion, regulation of T cell pools, as well as the modulation of macrophages polarization (23, 24). Only a few studies have evaluated L-Gal 9 expression in AT, and demonstrated that it is predominantly expressed in the stromal vascular fraction (SVF), composed of various cell types. It is possible that, overall, L-Gal 9 expression in the various AT compartments is similarly and tightly controlled. We observed lower CD206 expression in SAT and EAT compared to PAT in both groups, statistically significant in CHD patients only, possibly due to the lower number of CTRLs. This is in line with the different origin and vascularization of PAT (2, 7). Lower CD206 expression in EAT and SAT might be important because in concomitance with atherosclerosis progression the number of M2 macrophages in the plaques decreases (32) in various tissues including AT, with consequent formation of crown-like structures, a typical hallmark of chronic fat tissue inflammation that possibly hints CHD (33). We found NOS2 to be less expressed in EAT with respect to the other compartments, although statistical significance was reached only compared to SAT in the control group. Very recently, it was reported that adipocytes in EAT generated exosomes containing NOS2 (34). Thus, it is possible that the NOS2 we measured was adipocyte-derived, rather than of macrophage origin. Accordingly, its expression did not correlate with any macrophage, T cell or endothelial cell marker. The lower NOS2 expression in EAT in controls points to a specific, stricter regulation of this molecule in EAT, which might be lost in CHD (Graphical abstract, point a). Moreover, the EAT and SAT expression of NOS2 was positively associated only in the CHD group, in which also L-Gal 9 and CD206 were positively inter-correlated in EAT, suggesting activation of a compensatory anti-inflammatory mechanism specifically occurring in EAT in presence of CHD (Graphical abstract, point b).

In CHD patients, specifically in EAT, L-Gal 9 expression positively and strongly correlated to CD68 expression, a cellular marker identifying macrophages (35), thus the L-Gal 9 findings described above seems to be mainly related to its macrophage expression. As a consequence, the positive association observed specifically in EAT between L-Gal 9 and CD206 expression in CHD patients might confirm our hypothesis of a L-Gal 9 signaling toward an anti-inflammatory M2 profile in CHD patients, to compensate a local cardiac AT low-grade inflammation (36) (Graphical abstract, point b). Furthermore, specifically in PAT and EAT, a positive, albeit milder association was observed between L-Gal 9 and the expression of T cell receptor CD3. This is particularly of interest as several studies have demonstrated that L-Gal 9 acts also by binding and promoting the activity of death receptor 3, involved in the expansion of regulatory T cells number and activity (37), known to exert a fundamental role in AT homeostasis (38). CD206 gene expression was strongly associated with that of CD163 and CD68 in all AT analyzed. This could be expected as both CD206 and CD163 are commonly expressed by AT resident macrophages, mostly characterized by an M2-like signature (39, 40), while CD68 is commonly used as a macrophage-specific cell marker (35), regardless of the cell phenotype. Interestingly, specifically in PAT, we observed a positive association between CD31 expression, representing endothelial cells, and CD206. Notably, it has previously been demonstrated in humans that the vascular density and amount of endothelial cells in visceral AT is higher as compared to SAT, with a higher angiogenic and inflammatory profile (41). Furthermore, a pre-clinical model of infarcted rats showed that the administration of stem cells isolated from PAT promoted myogenic differentiation, with consequent efficient cardiac repair (42). Hence, the positive association that we observed between CD206 and CD31 expression selectively in PAT in CHD patients may be due to a possible reparatory mechanism.





     e-mail to a friend      printer-friendly     add to library      
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Financial Market Data provided by